BIIB091 (0.03-30 mg/kg; p.o. twice daily for 10 d) reduces the anti-NP IgM antibody titers (88%, 77%, 59%, 59%, 44%, 34%, and 22%) in the TI-2 immunization model[1].
Pharmacokinetics of BIIB091 in preclinical species[1]
| species | IV (1 mg/kg) | PO (5 mg/kg) in HMPC/Tween |
| T1/2 (h) | AUCinf (hng/mL) | CL (mL/min/kg) | CL %QH | Vdss (L/kg) | Tmax (h) | Cmax (ng/mL) | AUCinf (hng/mL) | %F |
| rat | 2.1 | 748 | 10 | 22 | 0.4 | 0.9 | 693 | 1522 | 42 |
| cyno | 1.1 | 943 | 18 | 44 | 0.7 | 0.33 | 1104 | 1446 | 31 |
| dog | 6.0 | 1675 | 12 | 33 | 1.7 | 1.6 | 1440 | 6075 | 89 |
| Animal Model: | C57BL/6 mice immunized with NP-Ficoll a thymus-independent type 2 (TI-2) antigen[1] |
| Dosage: | 0.03, 0.1, 0.3, 1, 10, 30 mg/kg in a CMC/Tween suspension formulation |
| Administration: | P.o. twice daily for 10 days |
| Result: | Observed a significant reduction of the anti-NP IgM antibody titers (88%, 77%, 59%, 59%, 44%, 34%, and 22%).
|
![1H-1,2,3-Triazole-4-carboxamide, 1-(1,1-dimethylethyl)-N-[(5R)-2,3,4,5-tetrahydro-8-[2-[(1-methyl-1H-pyrazol-4-yl)amino]-4-pyrimidinyl]-2-(3-oxetanyl)-1H-2-benzazepin-5-yl]- Structure](/CAS/20200611/GIF/2247614-80-6.gif)